Clinical development of KHK6640 for Alzheimer's disease
First written in FY2017-Q1. 15 of 19 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「In addition, we absorbed Imnas Pharma Co., Ltd., formerly our consolidated subsidiary, through a merger, with 28 March 2024 as the effective date. The merger was conducted as a simplified and short-form merger.」
The absorption merger of Imnas Pharma Co., Ltd. was completed on 28 March 2024. The company moved to the stage of integrating into our company its sales, research and development structure, including licensing-out activities for anti-amyloid-beta peptide antibodies. - FY2024-Q3ReframedAnnual report
「In addition, our consolidated subsidiary Imnas Pharma Co., Ltd. aims to pursue licensing-out activities for anti-amyloid-beta peptide antibodies and provide treatments for Alzheimer-type dementia. As announced on 5 February 2024, we resolved to absorb Imnas Pharma Co., Ltd., our wholly owned subsidiary, through a merger.」
The positioning changed from Kyowa Kirin-led clinical development of KHK6640 to licensing-out activities by Imnas Pharma, and the resolution to absorb the company through a merger was also disclosed. - FY2023ReframedAnnual report
「In addition, for strategic reasons, our consolidated subsidiary Imnas Pharma Co., Ltd. agreed with Kyowa Kirin Co.,Ltd. to terminate the agreement concerning the exclusive development, manufacturing and sales rights for anti-amyloid-beta peptide antibodies, including the grant of exclusive rights to use related patents and know-how. In connection with the termination, Imnas Pharma Co., Ltd. also agreed to acquire from Kyowa Kirin Co.,Ltd. the patent rights relating to the anti-amyloid-beta peptide antibodies. Going forward, Imnas Pharma Co., Ltd. aims to pursue licensing-out activities for anti-amyloid-beta peptide antibodies and provide treatments for Alzheimer-type dementia.」
The positioning changed from clinical development of KHK6640 led by Kyowa Kirin to a policy under which Imnas Pharma will pursue licensing-out activities following termination of the agreement and acquisition of the patent rights. - FY2023-Q3RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2023-Q1RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2022-Q3RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2022-Q1RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2021-Q3RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2021-Q2RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2021-Q1RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2020-Q3RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2020-Q2RestatedAnnual report
「Kyowa Kirin Co.,Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2018RestatedAnnual report
「Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2018-Q3RestatedAnnual report
「Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2018-Q2RestatedAnnual report
「Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2017RestatedAnnual report
「Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial of KHK6640 for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2017-Q3RestatedAnnual report
「In addition, with respect to the anti-amyloid-beta (Aβ) peptide antibody KHK6640, which our consolidated subsidiary Imnas Pharma Co., Ltd. has licensed out to Kyowa Hakko Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial for Alzheimer-type dementia in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2017-Q2RestatedAnnual report
「In addition, with respect to the anti-amyloid-beta (Aβ) peptide antibody KHK6640, which our consolidated subsidiary Imnas Pharma Co., Ltd. has licensed out to Kyowa Hakko Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial for Alzheimer’s disease in Europe and Japan.」
The disclosure continues to state that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan. - FY2017-Q1First statedAnnual report
「Imnas Pharma Co., Ltd., our consolidated subsidiary, has licensed out the anti-amyloid-beta (Aβ) peptide antibody KHK6640 to Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin Co., Ltd. is conducting a Phase I clinical trial for Alzheimer’s disease in Europe and Japan.」
In addition to the descriptions of the existing antibody-drug business and OTSA101, the disclosure states that Kyowa Hakko Kirin is conducting Phase I clinical trials of KHK6640 in Europe and Japan.